Skip to main content
Premium Trial:

Request an Annual Quote

Ferrer to be Agendia's Latin America Distributor

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia said today that it has hired Ferrer inCode to distribute its MammaPrint breast cancer diagnostic test in Latin America.

The MammaPrint test is used to identify patients who are at high risk of early metastasis and who are likely to develop metastases within five years after surgery.

Ferrer inCode is a subsidiary of Spain's Grupo Ferrer Internacional that is focused on personalized medicine, genomics, proteomics, and other related technologies.

"Ferrer has a strong presence in most of the Latin American key markets, most notably in rapidly emerging countries such as Brazil and Argentina, and has made great strides towards reimbursement in a number of Latin American countries," Bas van der Baan, Agendia's VP of commercial operation Europe/ROW, said in a statement.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.